Matt Hoffman, Associate Editorial Director for NeurologyLive®, has covered medical news for MJH Life Sciences, NeurologyLive®’s parent company, since 2017. He hosts the NeurologyLive® Mind Moments® podcast, as well as the Medical World News show, Deep Dive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com
Axsome Issued CRL for AXS-07 in Acute Migraine Treatment
May 2nd 2022Axsome expects to address the concerns in the letter and plans to resubmit AXS-07. The MoSEIC meloxicam-rizatriptan combination significantly reduced migraine symptoms and pain compared with placebo and both active agents in a pair of phase 3 trials.
The Big Data Revolution’s Role in Developing a Personalized Medicine Model
April 29th 2022Shurjal Baxi, MD, MPH, the senior vice president of Clinical and Scientific Solutions at Verana Health, shared her perspective on the AAN’s Axon Registry and how quality data collection can drive improvements in patient care and management.
Regenerative Medicine for Neurologic Injury and the Potential of SB623
April 29th 2022Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.
AAN Annual Meeting 2022: Top Expert Interviews
April 28th 2022Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.
Patient Survey Suggests Preference for Once-Nightly Dosing With FT218 in Narcolepsy
April 27th 2022Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.
Biogen Withdraws Aducanumab Application to EMA Shortly Following CMS National Coverage Determination
April 26th 2022Following an NCD that will allow for Medicare coverage of the therapy only in NIH- and FDA-approved studies and trials, Biogen has pulled its application to the European Medicines Agency for aducanumab treatment in Alzheimer disease.
Treatment Optimization in Epilepsy and the Need to Individualize the Approach
April 24th 2022Jacqueline A. French, MD, discussed the factors that influence the challenges in treatment selection in epilepsy, and how patient conversations and comprehension of heterogeneity can help in the treatment selection process.
AbbVie Pulls Out of Partnership With BioArctic for Parkinson Disease Candidates, Including ABBV-0805
April 21st 2022BioArctic CEO Gunilla Osswald, PhD, called the decision disappointing but noted that phase 1 data are supportive of ABBV-0805’s progression to phase 2 and that the company would “investigate options to continue the development” of the α-synuclein antibody.
FDA Extends Review of Vutrisiran for ATTR Amyloidosis 3 Months, Now Expected in July 2022
April 13th 2022Alnylam’s investigational subcutaneous RNAi therapy is in development for both wild-type and hereditary transthyretin-mediated amyloidosis, with data from the phase 3 HELIOS-A trial demonstrating its potential in treating associated polyneuropathy.
Ofatumumab Shows Long-term Safety and Efficacy, Does Not Restrict COVID-19 Vaccine Immune Response
April 10th 2022Data presented at the 2022 AAN Annual Meeting from the ALITHIOS and KYRIOS trials suggest that ofatumumab (Kesimpta; Novartis), an anti-CD20 therapy, is safe with up to 4 years of treatment and does not prevent the mounting of an immune response to mRNA vaccines.
Episode 61: 2022 AAN Annual Meeting Highlights
April 9th 2022Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]
Improving Care for Adults With Intellectual and Developmental Disabilities
April 7th 2022Seth M. Keller, MD, chair of the Section for Adults With IDDs at AAN, shared his perspective on the state of care for these individuals and the need to improve the difficulties they face when transitioning out of pediatric care.
Combination Agent P2B001 Shows Promise for Parkinson Disease in Phase 3 Data
April 5th 2022The Pharma Two B therapy combines a dopamine agonist, pramipexole, and an MAO-B inhibitor, rasagiline, and has shown significant improvements on UPDRS total scores and ESS scores for untreated patients with PD.
Ocrelizumab Shows Improved Cognition, Low Disease Activity in Progressive MS Interim Data
April 5th 2022One-year data from the single-arm phase 3b CONSONANCE trial (NCT03523858) suggest that the Genentech agent (Ocrevus) resulted in low levels of disease activity and improved cognitive performance in those with secondary and primary progressive multiple sclerosis.
Targeting Senescent Cells to Address Alzheimer Disease and Neurodegeneration
April 4th 2022In an AAN 2022 Hot Topics plenary session, Miranda E. Orr, PhD, highlighted the potential of targeting senescent cells with senolytics as a therapeutic approach to age-related diseases such as Alzheimer disease, and detailed the ongoing phase 2 SToMP-AD clinical trial (NCT04685590).